Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 1;13(7):1663.
doi: 10.3390/cancers13071663.

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Alice Indini  1 , Olga Nigro  2 , Csongor György Lengyel  3 , Michele Ghidini  4 , Angelica Petrillo  5 , Salvatore Lopez  6 , Francesco Raspagliesi  6 , Dario Trapani  7 , Shelize Khakoo  8 , Giorgio Bogani  6
Affiliations
Review

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Alice Indini et al. Cancers (Basel). .

Abstract

Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and other targeted agents. The role of immunotherapy in the treatment of platinum-resistant OC remains undefined. The aim of this review is to describe the immunobiology of OC and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration, as well as provide an overview of future drug development strategies.

Keywords: immune checkpoint inhibitors; immunotherapy; new drugs; ovarian cancer; platinum-resistance.

PubMed Disclaimer

Conflict of interest statement

D.T.; A.I.; M.G.; S.K.; G.B. have no COI to disclose. A.P. reports personal fees from Eli Lilly, outside the submitted work. C.G.L. reports employment by Bristol Myers Squibb.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of inci-dence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Noone A.M., Howlader N., Krapcho M., Miller D., Brest A., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., et al. SEER Can-cer Statistics Review, 1975–2015, National Cancer Institute. Bethesda, MD. [(accessed on 1 April 2021)]; Available online: https://seer.cancer.gov/csr/1975_2017/
    1. Raspagliesi F., Bogani G., Benedetti S., Grassi S., Ferla S., Buratti S. Detection of Ovarian Cancer through Exhaled Breath by Electronic Nose: A Prospective Study. Cancers. 2020;12:2408. doi: 10.3390/cancers12092408. - DOI - PMC - PubMed
    1. Duska L.R., Kohn E.C. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical im-plications. Ann. Oncol. 2017;28:viii8–viii12. doi: 10.1093/annonc/mdx445. - DOI - PMC - PubMed

LinkOut - more resources